RT @synovialjoints: Prevention study using Abatacept in 100 patients with arthralgia is superior (61%) to placebo (31%)
Tweet Content
Prevention study using Abatacept in 100 patients with arthralgia is superior (61%) to placebo (31%) in improving subclinical inflammation in RA at-risk patients (ACPA+, MRI+, Arthralgia+) at 6 months. No new safety issue emerged @RheumNow #ACR21 Abst#0455 https://t.co/DoRItcHfBE
Links
Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop …
https://bit.ly/3wlgIPb
Show on Archive Page
On
Display in Search Results
On
PDQ
Off